Relypsa (RLYP) Could Be Next High-Profile Takeout, Says Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data cuts rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform
November 9, 2015 9:36 AM ESTLeerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.
Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More
AstraZeneca/ZSHP Acquisition Highlights Relypsa (RLYP) is Undervalued - Oppenheimer
November 9, 2015 9:33 AM ESTOppenheimer analyst, Ling Wang, believes Relypsa (NASDAQ: RLYP) is undervalued after the acquisition of ZSPH at a value of $2.7B. Competitor ZS-9's interim 52-week data were presented from phase III ZS-005 trial and Wang believes the drugs presented by each company have comparable... More
Relypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal
November 6, 2015 6:53 AM ESTRelypsa (NASDAQ: RLYP) shares are poised higher after AstraZeneca (NYSE: AZN) agreed to acquire ZS Pharma (NASDAQ: ZSPH) for $2.7 billion. Shares of Relypsa are set to open higher by 20%.
... More